Skip to main content
. 2023 Oct 5;29(3):e372–e381. doi: 10.1093/oncolo/oyad273

Table 2.

Patient clinicopathological and metabolic characteristics according to LIPID score (n = 316).

Characteristics Good risk group
(TC ≥ 200 mg/dl and TG < 150 mg/dl)
(n = 60)
Intermediate risk group
TC < 200 mg/dl and TG < 150 mg/dl or TC ≥ 200 mg/dl and TG  ≥ 150 mg/dl
(n = 201)
Poor risk group
TC < 200 mg/dl and TG ≥ 150 mg/dl
(n = 55)
P
Age at ICI start
 Median (range) 66.0 (41.0-81.0) 68.0 (31.0-89.0) 69.0 (38.0-86.0) .09
Sex
 Female 29 (48.3%) 68 (33.8%) 14 (25.5%) .03
 Male 31 (51.7%) 133 (66.2%) 41 (74.5%)
Tumor type
 NSCLC 39 (65.0%) 128 (63.7%) 34 (61.8%) .93
 Others* 21 (35.0%) 73 (36.3%) 21 (38.2%)
Treatment type
 ICI 49 (81.7%) 174 (86.6%) 52 (94.5%) .09
 ICI plus chemotherapy 6 (10.0%) 7 (3.5%) 1 (1.8%)
 ICI plus TKI 5 (8.3%) 20 (9.9%) 2 (3.6%)
Treatment line
 First 35 (58.3%) 105 (52.2%) 30 (54.5%) .70
 ≥Second 25 (41.7%) 96 (47.7%) 25 (45.5%)
ECOG PS
 0-1 59 (98.3%) 178 (88.6%) 42 (76.4%) .01
 ≥ 2 1 (1.7%) 23 (11.4%) 13 (23.6%)
Metastatic sites
 0-1 13 (21.7%) 31 (15.4%) 11 (20.0%) .45
 ≥ 2 47 (78.3%) 170 (84.6%) 44 (80.0%)
Diagnosis of DM
 No 56 (93.3%) 163 (81.1%) 39 (70.9%) .007
 Yes 4 (6.7%) 38 (18.9%) 16 (29.1%)
CV disease
 No 48 (80.0%) 141 (70.2%) 32 (58.2%) .02
 Yes 11 (18.3%) 60 (29.8%) 23 (41.8%)
 NA 1 (1.7%) 0 (0%) 0 (0%)
Hypertension
 No 25 (41.7%) 92 (45.8%) 13 (23.6%) .01
 Yes 35 (58.3%) 109 (54.2%) 42 (76.4%)
Statin use
 No 55 (91.7%) 149 (74.1%) 28 (50.9%) <.001
 Yes 4 (6.7%) 51 (25.4%) 27 (49.1%)
 NA 1 (1.7%) 1 (0.5%) 0 (0%)
Smoking status
 Current/former smoker 37 (61.7%) 117 (58.2%) 21 (38.2%) .99
 Never 23 (38.3%) 75 (37.3%) 33 (60.0%)
 NA 0 (0%) 9 (4.5%) 1 (1.8%)
BMI (kg/m2)
< 25
 Underweight
(BMI < 18.5)
2 (3.3%) 6 (3.0%) 2 (3.6%) .31
 Normal
(18.5 ≤ BMI ≤ 24.9)
30 (50.0%) 108 (53.7%) 23 (41.8%)
 ≥ 25
 Overweight
(25 ≤ BMI ≤ 29.9)
10 (16.7%) 28 (13.9%) 8 (14.5%)
 Obese
(BMI ≥ 30)
15 (25.0%) 58 (28.8%) 22 (40.0%)
 NA 3 (5.0%) 1 (0.5%) 0 (0%)
BMI (kg/m2)
 Median (range) 24.1 (16.4-34.3) 24.2 (13.5-43.2) 25.5 (14.7-39.8) .13
HDL
 Median (range) 63 (38-112) 50 (12-87) 40 (23-73) <.001
LDL
 Median (range) 137 (78-271) 92 (22-219) 86 (26-133) <.001

*Others: Renal cell carcinoma, melanoma, urothelial carcinoma, head and neck carcinoma, small cell lung cancer, and breast cancer.

Abbreviations: ICI: immune checkpoint inhibitor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor; ECOG PS: Performance Status according to Eastern Cooperative Oncology Group; DM: diabetes mellitus; BMI: body mass index (kg/m2); CV: cardiovascular, NA: not available.